BR0207819A - Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìna - Google Patents
Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìnaInfo
- Publication number
- BR0207819A BR0207819A BR0207819-8A BR0207819A BR0207819A BR 0207819 A BR0207819 A BR 0207819A BR 0207819 A BR0207819 A BR 0207819A BR 0207819 A BR0207819 A BR 0207819A
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- preparation
- methods
- cytokine
- vector
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 102000004127 Cytokines Human genes 0.000 title abstract 3
- 108090000695 Cytokines Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- -1 host Substances 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 241000282412 Homo Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0105360.2A GB0105360D0 (en) | 2001-03-03 | 2001-03-03 | Chimaeric immunogens |
| PCT/GB2002/000900 WO2002070711A1 (en) | 2001-03-03 | 2002-03-01 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0207819A true BR0207819A (pt) | 2004-03-02 |
Family
ID=9909970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0207819-8A BR0207819A (pt) | 2001-03-03 | 2002-03-01 | Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìna |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20050260216A1 (enExample) |
| EP (1) | EP1368477A1 (enExample) |
| JP (1) | JP4238031B2 (enExample) |
| KR (1) | KR20030081490A (enExample) |
| CN (1) | CN1543504A (enExample) |
| AU (1) | AU2002233560B2 (enExample) |
| BR (1) | BR0207819A (enExample) |
| CA (1) | CA2439628A1 (enExample) |
| CZ (1) | CZ20032373A3 (enExample) |
| GB (1) | GB0105360D0 (enExample) |
| HU (1) | HUP0303372A3 (enExample) |
| IL (1) | IL157498A0 (enExample) |
| MX (1) | MXPA03007915A (enExample) |
| NO (1) | NO20033882L (enExample) |
| NZ (1) | NZ527873A (enExample) |
| PL (1) | PL365066A1 (enExample) |
| WO (1) | WO2002070711A1 (enExample) |
| ZA (1) | ZA200306647B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA77152C2 (en) * | 1999-09-25 | 2006-11-15 | Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma | |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| CA2496409A1 (en) * | 2002-08-30 | 2004-03-11 | Glaxo Group Limited | Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use |
| JP2006503018A (ja) * | 2002-08-30 | 2006-01-26 | グラクソ グループ リミテッド | ワクチン |
| EP1539232A1 (en) * | 2002-09-12 | 2005-06-15 | Pharmexa A/S | Immunization against autologous ghrelin |
| US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| EP1594533B1 (en) * | 2003-01-31 | 2012-04-11 | Celldex Research Corporation | Antibody vaccine conjugates and uses therefor |
| JP2007525436A (ja) * | 2003-03-24 | 2007-09-06 | マーシア・ファーマ・インコーポレイテッド | 炎症症状を処置および予防するための方法および組成物 |
| WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| EP1767216B1 (en) * | 2004-06-11 | 2012-07-11 | Riken | Drug having regulatory cell ligand contained in liposome |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US8273361B2 (en) | 2006-09-26 | 2012-09-25 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| RU2009140134A (ru) * | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
| JP2010527633A (ja) * | 2007-05-25 | 2010-08-19 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Ｔｏｌｌ様受容体３モジュレーター及びその使用 |
| BRPI0820270A2 (pt) * | 2007-11-07 | 2015-06-16 | Celldex Therapeutics Inc | Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular. |
| LT2850431T (lt) | 2012-05-16 | 2018-06-25 | Immune Design Corp. | Vakcinos, skirtos hsv-2 |
| KR102039520B1 (ko) | 2013-04-18 | 2019-11-01 | 이뮨 디자인 코포레이션 | 암 치료에 이용하기 위한 gla 단일요법 |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| AU2022212600A1 (en) * | 2021-01-29 | 2023-08-17 | Bayer Animal Health Gmbh | Vaccine composition for breaking self-tolerance |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) * | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5697901A (en) * | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| AU661684B2 (en) * | 1991-06-18 | 1995-08-03 | Regents Of The University Of California, The | Cloned glutamic acid decarboxylase |
| DE4137333A1 (de) * | 1991-11-13 | 1993-05-19 | W Prof Dr Sebald | Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung |
| EP0772619B2 (en) * | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AU3382595A (en) * | 1994-07-29 | 1996-03-04 | Smithkline Beecham Corporation | Novel compounds |
| US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| ES2289751T3 (es) * | 1995-02-20 | 2008-02-01 | The Walter And Eliza Hall Institute Of Medical Research | Moleculas inmunorreactivas e inmunoterapeuticas que interaccionan en sujetos con diabetes mellitus insulinodependientes (dmid). |
| US6518061B1 (en) * | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US5614191A (en) * | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| EP0759468A1 (en) * | 1995-08-10 | 1997-02-26 | Laboratoires Virbac | Feline interleukin-4 |
| US5666153A (en) * | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
| US6664227B1 (en) * | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| US5843449A (en) * | 1996-03-25 | 1998-12-01 | Akzo Nobel N.V. | Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases |
| US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| EP1012184B1 (en) * | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| EP0911401A1 (en) * | 1997-10-21 | 1999-04-28 | Bayer Ag | Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain |
| EP1071333A4 (en) * | 1998-03-20 | 2005-02-23 | Genzyme Corp | INDUCTION OF IMMUNITY AGAINST TUMOR AUTOANTIGENS |
| US6576232B1 (en) * | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
| AU5617900A (en) * | 1999-06-17 | 2001-01-09 | Robert C. Gallo | Chimeric chemokine-antigen polypeptides and uses therefor |
| AU1599301A (en) * | 1999-11-11 | 2001-06-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13 |
-
2001
- 2001-03-03 GB GBGB0105360.2A patent/GB0105360D0/en not_active Ceased
-
2002
- 2002-03-01 BR BR0207819-8A patent/BR0207819A/pt not_active IP Right Cessation
- 2002-03-01 AU AU2002233560A patent/AU2002233560B2/en not_active Ceased
- 2002-03-01 HU HU0303372A patent/HUP0303372A3/hu unknown
- 2002-03-01 JP JP2002570736A patent/JP4238031B2/ja not_active Expired - Fee Related
- 2002-03-01 KR KR10-2003-7011573A patent/KR20030081490A/ko not_active Ceased
- 2002-03-01 EP EP02700490A patent/EP1368477A1/en not_active Withdrawn
- 2002-03-01 CZ CZ20032373A patent/CZ20032373A3/cs unknown
- 2002-03-01 CA CA002439628A patent/CA2439628A1/en not_active Abandoned
- 2002-03-01 IL IL15749802A patent/IL157498A0/xx unknown
- 2002-03-01 WO PCT/GB2002/000900 patent/WO2002070711A1/en not_active Ceased
- 2002-03-01 PL PL02365066A patent/PL365066A1/xx unknown
- 2002-03-01 US US10/469,561 patent/US20050260216A1/en not_active Abandoned
- 2002-03-01 CN CNA028093240A patent/CN1543504A/zh active Pending
- 2002-03-01 MX MXPA03007915A patent/MXPA03007915A/es not_active Application Discontinuation
- 2002-03-01 NZ NZ527873A patent/NZ527873A/en unknown
- 2002-09-03 US US10/233,902 patent/US20030194391A1/en not_active Abandoned
-
2003
- 2003-08-26 ZA ZA200306647A patent/ZA200306647B/en unknown
- 2003-09-02 NO NO20033882A patent/NO20033882L/no not_active Application Discontinuation
-
2005
- 2005-01-24 US US11/041,636 patent/US20050186209A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030081490A (ko) | 2003-10-17 |
| JP4238031B2 (ja) | 2009-03-11 |
| US20050186209A1 (en) | 2005-08-25 |
| GB0105360D0 (en) | 2001-04-18 |
| HUP0303372A2 (hu) | 2004-01-28 |
| NO20033882D0 (no) | 2003-09-02 |
| CN1543504A (zh) | 2004-11-03 |
| MXPA03007915A (es) | 2003-12-04 |
| NZ527873A (en) | 2005-12-23 |
| JP2005502314A (ja) | 2005-01-27 |
| CA2439628A1 (en) | 2002-09-12 |
| NO20033882L (no) | 2003-10-31 |
| EP1368477A1 (en) | 2003-12-10 |
| US20050260216A1 (en) | 2005-11-24 |
| IL157498A0 (en) | 2004-03-28 |
| PL365066A1 (en) | 2004-12-27 |
| HUP0303372A3 (en) | 2008-06-30 |
| CZ20032373A3 (cs) | 2004-01-14 |
| AU2002233560B2 (en) | 2006-09-07 |
| WO2002070711A1 (en) | 2002-09-12 |
| US20030194391A1 (en) | 2003-10-16 |
| ZA200306647B (en) | 2004-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0207819A (pt) | Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìna | |
| JP2021152017A (ja) | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 | |
| ES2676824T3 (es) | Proteínas GST de 28 KDa que provienen de esquistosomas para su utilización en el tratamiento de enfermedades inflamatorias autoinmunes que generan una respuesta de tipo Th1 y/o Th17 | |
| WO2020252418A3 (en) | Novel interleukin-2 variants for the treatment of cancer | |
| BR0206289A (pt) | Processos de administração de anticorpos anti-tnf(alfa) | |
| CA2688766C (en) | Compositions and methods for treatment of multiple sclerosis | |
| BR0107972A (pt) | Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano | |
| BRPI0415304A (pt) | métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou variante bioativos, e de uma composição imunogênica | |
| MY145790A (en) | Composition | |
| HUP0000299A1 (hu) | Késleltetett hatóanyag-leadású gyógyszerkészítmények | |
| BR0114786A (pt) | Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição | |
| BRPI0415315A (pt) | métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou derivado bioativos, e de uma composição imunogênica | |
| BR0208041A (pt) | Interferon beta modificado com imunogenicidade reduzida | |
| AU1813701A (en) | Interleukin-1 muteins useful as vaccine adjuvants | |
| ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| JP2013544244A (ja) | 抗炎症組成物 | |
| KR20170055550A (ko) | 신규 펩타이드 및 이의 용도 | |
| WO2002062833A3 (en) | Modified leptin with reduced immunogenicity | |
| JP2018526459A (ja) | 脊椎関節症の処置のためのインターロイキン−２の使用 | |
| ES2547379T3 (es) | Utilización de calcitonina para el tratamiento de la AR | |
| BR0207704A (pt) | Alfa interferon modificado com imunogenicidade reduzida | |
| BR0207945A (pt) | Fator estimulante de colÈnia de macrófagos granulócitos modificados (gm-csf) com reduzida imunogenicidade | |
| BR0207905A (pt) | Protamina modificada com imunogenicidade reduzida | |
| ES2634256T3 (es) | Composiciones innovadoras y usos de las mismas | |
| BR0207705A (pt) | Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010. |